Drug Profile of Emtricitabine and Tenofovir AF

Authors

  • N. MD. Akram  Research Scholar, Department of Chemistry, Rayalaseema University, Kurnool, Andhra Pradesh, India
  • Dr. M. Umamahesh  Professor & HOD of chemistry, Rajeev Gandhi Memorial College of Engineering & Technology (RGMCET), Nandyal, Kurnool (Dt). Andhra Pradesh, India

Keywords:

Emtricitabine, Tenofovir alafenamide, NRTI.

Abstract

Emtricitabine and Tenofovir alafenamide (tenofovir AF) is a novel oral prodrug of the nucleos(t)ide reverse transcriptase inhibitor (NRTI) tenofovir that has several pharmacological advantages over tenofovir disoproxil fumarate (tenofovir DF), including increased plasma stability and reduced tenofovir systemic exposure. Tenofovir AF has been coformulated with emtricitabine for the treatment of adults and adolescents with HIV-1 infection.

References

  1. Masho SW, Wang CL, Nixon DE: Review of tenofovir-emtricitabine. Ther Clin Risk Manag. 2007 Dec;3(6):1097-104. [PubMed:18516268 ]
  2. Long MC, King JR, Acosta EP: Pharmacologic aspects of new antiretroviral drugs. Curr HIV/AIDS Rep. 2009 Feb;6(1):43-50. [PubMed:19149996 ]
  3. Authors unspecified: Emtricitabine/tenofovir disoproxil fumarate. Drugs R D. 2004;5(3):160-1. [PubMed:15139777 ]
  4. Goicoechea M, Best B: Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all? Expert Opin Pharmacother. 2007 Feb;8(3):371-82. [PubMed:17266471 ] .
  5. Benhamou Y, Tubia R, Thibault V. Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. New Engl J Med. 2003;348:177-8. [PubMed]

Downloads

Published

2018-04-30

Issue

Section

Research Articles

How to Cite

[1]
N. MD. Akram, Dr. M. Umamahesh, " Drug Profile of Emtricitabine and Tenofovir AF, International Journal of Scientific Research in Science, Engineering and Technology(IJSRSET), Print ISSN : 2395-1990, Online ISSN : 2394-4099, Volume 4, Issue 4, pp.300-303, March-April-2018.